Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote

AstraZeneca clinched an FDA accelerated approval for its oral SERD in certain breast cancer patients Friday, even after a negative vote from the agency’s advisory committee in April. Camizestrant, with the brand ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 7 September →